{"id":"anti-r-il2-cyclosporine","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Tremor"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The anti-IL-2 receptor (anti-IL2R) monoclonal antibody blocks the high-affinity IL-2 receptor on activated T lymphocytes, preventing IL-2-driven proliferation. Cyclosporine is a calcineurin inhibitor that suppresses T-cell activation by blocking IL-2 transcription. Together, this combination provides dual immunosuppression targeting different steps of T-cell activation, reducing rejection risk in transplantation.","oneSentence":"Anti-IL-2 receptor antibody combined with cyclosporine suppresses T-cell activation and proliferation to prevent organ rejection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:56.186Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of acute organ rejection in transplant recipients"}]},"trialDetails":[{"nctId":"NCT06504225","phase":"","title":"EVEROLD LONG TERM FOLLOW-UP","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2024-08-23","conditions":"Transplant; Complication, Failure","enrollment":260},{"nctId":"NCT01028092","phase":"PHASE3","title":"mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2009-03","conditions":"Renal Transplant","enrollment":327}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Anti R-IL2 + Cyclosporine","genericName":"Anti R-IL2 + Cyclosporine","companyName":"University Hospital, Brest","companyId":"university-hospital-brest","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anti-IL-2 receptor antibody combined with cyclosporine suppresses T-cell activation and proliferation to prevent organ rejection. Used for Prevention of acute organ rejection in transplant recipients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}